Anglo Pacific #APF is a commodity royalty company, dividend is about 7% but it doesn't look too sustainable or real.
Ultimately royalty companies are easy: receive dividends, buy more royalties and pay cash to shareholders. All works out until 2014-15 and since then, not so much
The way the whole thing has been sustained since, has been by debt and printing shares. This isn't to say this won't work without a turn in commodities - it will, although there's debt here that wasn't before - otherwise the divi gets cut or shareholders will print it themselves.
In number form in case the my-first-crayon palette is just too much to take.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
This is again the idea: Pfizer wants to get a powder version of the Covid vaccine in order to avoid the cold-chain issues and expenses associated with the first-gen vaccine
- I am far, far out of my lane looking at this
- The comp lives in a bubble market
- This is 100% based on crude pattern recognition
- Market appears to value #RENE for other aspects, so
- This may not work even if the idea proves correct
So, #RENE may have what may be one of the Next Big Things: a platform for the cutting edge of genetic medicine - the comp lives off that alone.
In English, they use "exosomes" to try to get mRNA and CRISPR molecules past the blood-brain barrier into the brain. See below
Tiny, UK AIM co in specialty chemicals: specifically "sustainable polymers"
At best this usually means 1 client and a test batch; at worst, magic beans
But Itaconix #ITX is neither and it's rather mispriced: it sells at margins that rival the best in the world - and in size
It may actually be very mispriced; estimates are clearly too low. All in part because it's off the radar.
It's another find by @dopamine_uptake who pointed it out to me after reading on IP Group - some holdings of theirs caught his eye and of them, this one really caught mine.
I'll get straight to it. HY20 end October.
We see revenues up +80% on the previous year's half and they're not far off equaling the whole of 2019's revenues.
- history of over promising and disappointing
- very much a AIM small cap
- burns cash
- will place and dilute
- has share price on homepage
- Glassdoor is not great
- emoji issues when discussed
*But* it may now be delivering for real. If so it may also be extremely cheap. How cheap?
20H1 was 2x sequentially and 10x YoY
It may be about to report H1-H2 sequential growth of 5x.
If so, FY20: 10x YoY.
Fwd 21 rev multiple? Perhaps half that number, perhaps even less.
T9M figures last 4 years. Yes it's a bit stagnant in the numbers and costs up / profit down a little etc but the COGs numbers are roughly consistent. You could imagine a jump in revenues flowing through quite well.
2018 was Oprah
Fair to guess lots of New Year gym sign-ups are postponed or never happen and more NY lose weight / get fit resolutions than usual find their way here instead?
Cashflow behaves roughly the same. More SBC, bit more capex.